Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-124343
Filing Date
2024-11-12
Accepted
2024-11-08 20:46:03
Documents
64
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q apto-20240930.htm   iXBRL 10-Q 1631700
2 EX-10.1 apto-ex10_1.htm EX-10.1 194519
3 EX-31.1 apto-ex31_1.htm EX-31.1 15876
4 EX-31.2 apto-ex31_2.htm EX-31.2 13575
5 EX-32.1 apto-ex32_1.htm EX-32.1 6380
6 EX-32.2 apto-ex32_2.htm EX-32.2 6385
7 GRAPHIC img239731369_0.jpg GRAPHIC 5225
  Complete submission text file 0000950170-24-124343.txt   7297163

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT apto-20240930.xsd EX-101.SCH 1222230
67 EXTRACTED XBRL INSTANCE DOCUMENT apto-20240930_htm.xml XML 1074016
Mailing Address 66 WELLINGTON STREET WEST, SUITE 5300 TD BANK TOWER BOX 48 TORONTO A6 M5K 1E6
Business Address 66 WELLINGTON STREET WEST, SUITE 5300 TD BANK TOWER BOX 48 TORONTO A6 M5K 1E6 310-849-8060
Aptose Biosciences Inc. (Filer) CIK: 0000882361 (see all company filings)

EIN.: 000000000 | State of Incorp.: A6 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-32001 | Film No.: 241442583
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)